Redsense Medical

Redsense is evaluating the potential effects of new global tariffs announced by President Donald Trump on its operations. The company is in communication with customs brokers, U.S. distribution partners, and customers to monitor the situation and coordinate responses. The impact on medical devices is still uncertain, but Redsense is closely observing developments, including discussions by Medtech groups with the White House. CEO Sebastien Bollue stated that they have sufficient product stock in the U.S. to meet customer demand in the short term. Meanwhile, the launch of the Redsense Clamp, planned for Q1 2025, is delayed due to review processes affected by the high workload from MDR implementation. Redsense is actively engaged with the review process and ready to proceed once approval is received. For more information, contact Sebastien Bollue, CEO, at +46 72-171 1264 or sebastien.bollue@redsensemedical.com.

During the period from October to December 2024, Redsense Medical reported net sales of 12,687 kSEK, a significant increase from the previous year's 8,025 kSEK. The operating profit (EBIT) was 5,525 kSEK, and the result after tax was 5,629 kSEK, both showing a substantial improvement from negative figures the previous year. Earnings per share rose to SEK 0.34. Other operating income/loss was 1,771 kSEK. Significant events included the appointment of the nomination committee for the 2025 Annual General Meeting and the decision not to renew the agreement with OTC Markets Group, ending trading on the OTCQX platform in the USA. After the period, Redsense completed the usability testing phase of the Redsense Clamp, announced the passing of Board Member Malin Almgren, and appointed a new CFO along with part-time support functions. CEO Sebastien Bollue highlighted a strong end to 2024 with record sales and a positive full-year result for the first time in the company's history. The company is focusing on improving operations, strengthening partnerships, and enhancing internal processes. Efforts to secure U.S. reimbursement are ongoing, with the HCPCS application under review. The commercial launch of the Redsense Clamp is planned for early 2025. The company is investing in team and operational improvements to support strategic objectives and anticipates growth and expansion in 2025.

Redsense Medical has announced that Peter Larsson will become the new CFO, succeeding Jennie Kardell, who is leaving to pursue other opportunities. Larsson, with over 30 years of experience in financial leadership roles, will join as a part-time CFO consultant. CEO Sebastien Bollue expressed enthusiasm about Larsson's appointment and thanked Kardell for her contributions. Additionally, Redsense will be supported by a Postdoc intern from Karolinska Institute and a master's student from Halmstad University, both working part-time. These new team members will assist in areas such as health economics research, communication, regulatory affairs, supply chain management, quality management, and sustainability. Bollue highlighted the importance of these additions in supporting the company's growth.

Redsense Medical meddelar att Malin Almgren, en engagerad styrelsemedlem sedan maj 2023, hastigt har avlidit. Hon bidrog med värdefulla insikter baserade på sin starka forskningsinriktning. Susanne Olauson, styrelseordförande, uttrycker att Malin kommer att bli ihågkommen för sin lugna närvaro och skarpa intellekt. Styrelsens valberedning kommer att föreslå nya styrelsemedlemmar inför det kommande årsmötet. För mer information kan Susanne Olauson kontaktas.